Red blood cell wide variety of endogenous mediators and xenobiotics. Excessive eryptosis is observed in red blood cells lacking the cGMP-dependent protein kinase type I or the AMP-activated protein kinase AMPK. Inhibitors of eryptosis include erythropoietin, nitric oxide, catecholamines and high concentrations of urea. Much of the resulting breakdown products are recirculated in the body. The heme constituent of hemoglobin are broken down into iron (Fe) and biliverdin. The biliverdin is reduced to bilirubin, which is released into the plasma and recirculated to the liver bound to albumin. The iron is released into the plasma to be recirculated by a carrier protein called
Genetically engineered blood Genetically engineered blood Genetically engineered blood is blood that has been modified for therapeutic or other purposes. Genetically modifying red blood stem cells allows them to produce specific therapeutic proteins on the surface or inside the cell. The stem cells are taken from mammalian bone marrow and are modified in culture. Before they become mature, mammalian red blood cells eject their genetic material. Culturing cells that produce a new protein of interest requires only a few weeks. Using the sortagging protein labeling technique, the researchers used the bacterial enzyme sortase A to establish a strong chemical bond between the surface